Latest Headlines

Latest Headlines

Aesica teams with QRxPharma for abuse-deterrence tech

Aesica has struck a deal with Australia's QRxPharma, agreeing to promote the company's abuse-deterrence technology to its clients manufacturing controlled drugs.

Pain tablet has sustained-release pharmacokinetic profile

QRxPharma has announced the results of a Phase I trial for MoxDuo CR, a controlled-release Dual-Opioid designed to provide 12 hours of pain relief in patients suffering from moderate to severe